Hikal Limited reported a consolidated net loss of ₹74 million for the quarter ended June 30, 2026, a significant improvement from the ₹224 million loss recorded in the corresponding period of FY25. The company's total revenue from operations rose 6% year-on-year to ₹4,028 million, driven primarily by growth in its Pharmaceuticals segment. Standalone results mirrored this trend, with a net loss of ₹75 million compared to ₹227 million in Q1FY25. The narrowing loss reflects better operational performance in key segments and favorable exceptional items, including a ₹89 million reduction in employee benefit liabilities due to salary restructuring.

The Board of Directors approved the unaudited financial results at a meeting held on August 06, 2026. The results were reviewed by the Audit Committee on August 05, 2026. S R B C & Co LLP, the statutory auditor, issued an unmodified limited review report pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The trading window for designated persons will re-open on August 09, 2026, following its closure since July 01, 2026.

Segment Performance

The Pharmaceuticals segment contributed ₹2,333 million to revenue, up from ₹2,026 million in Q1FY25. It returned to profitability with a segment result of ₹75 million, reversing a loss of ₹261 million in the prior year. In contrast, the Crop Protection segment saw revenue decline to ₹1,695 million from ₹1,778 million, reporting a segment loss of ₹60 million compared to a profit of ₹173 million previously. This divergence highlights shifting demand dynamics and potential regulatory headwinds in the agrochemical space.

Key Financial Metrics

Hikal's operational efficiency showed marked improvement, with EBITDA rising to ₹370 million from ₹251 million in Q1FY25, while EBITDA margin expanded to 9.20% from 6.60% over the same period. Total expenses stood at ₹4,234 million, slightly lower than the ₹4,235 million incurred in the standalone books. Finance costs remained stable at ₹149 million. Depreciation and amortization expenses increased to ₹427 million from ₹394 million in Q1FY25. Other income was ₹18 million, down from ₹66 million in the previous quarter but up from ₹10 million in Q1FY25. Tax expense was ₹25 million, comprising deferred tax only, as current tax was nil following a reversal of provisions.

What the Numbers Show

The improvement in net loss is largely attributable to the Pharmaceuticals segment's return to profitability, a ₹89 million exceptional gain from salary restructuring, and a meaningful expansion in EBITDA margins. However, the Crop Protection segment's decline signals ongoing challenges, potentially exacerbated by the USFDA warning letter issued in August 2025 regarding the Jigani facility, which continues to impact Pharma sales. Additionally, the company faces legal uncertainty over alleged environmental non-compliance, with a matter pending before the Supreme Court of India involving a potential compensation of ₹174.5 million, though no further provision has been made as of this quarter.

Hikal Limited will host an earnings group conference call on Thursday, August 06, 2026, at 5:00 PM IST to discuss its financial and operational performance for the quarter ended June 30, 2026. The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, providing investors with a direct channel to management for insights into Q1FY27 results. The company notified both the Bombay Stock Exchange and the National Stock Exchange of India Limited regarding the event. The intimation dated July 30, 2026, was signed by Company Secretary Rajasekhar Reddy Chintakindi, ensuring compliance with regulatory disclosure norms.

Conference Call Participants

Senior leadership from Hikal Limited will participate in the discussion to provide detailed commentary on the quarter's performance. The key participants are as follows:

Dial-In Details

Investors and analysts can join the call using the provided dial-in numbers. Strategic Growth Advisors Pvt. Ltd. is facilitating the registration process.

For RSVP inquiries, investors may contact Mr. Jigar Kavaiya at jigar.kavaiya@sgapl.net or Ms. Ami Parekh at ami.parekh@sgapl.net .

What This Means for Investors

The conference call serves as a critical platform for stakeholders to understand the drivers behind Hikal Limited's Q1FY27 financial results. With participation from the CFO and business heads, the session is expected to cover segment-wise performance, particularly in Pharmaceuticals and Animal Health, as well as broader business transformation initiatives. Investors should note that no specific financial figures were disclosed in this announcement; all material data will be presented during the live discussion.